- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears AI-Powered Stroke Imaging Tool for Non-Contrast CT
Through artificial intelligence (AI) assessment of non-contrast computed tomography (CT) scans, the Brainomix 360 e-ASPECTS software provides an automated ASPECTS score and heatmap to enhance stroke imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Brainomix 360 e-ASPECTS software (Brainomix), which provides adjunctive artificial intelligence (AI) assessment of computed tomography (CT) scans of the brain and automated scoring with the Alberta Stroke Program Early CT score (ASPECTS) system.
As part of the Brainomix 360 stroke platform, which emphasizes real-time AI-enabled interpretation of brain imaging in stroke patients, the e-ASPECTS software provides enhanced heatmap visualization and automated ASPECTS scoring based on non-contrast CT scans, according to Brainomix.
The company said recent studies have demonstrated the stroke imaging platform’s ability to reduce door-in door-out times and reportedly triple the number of patients regaining functional independence after stroke.
“Our e-ASPECTS tool has been shown, in multiple countries and healthcare systems, to improve physicians’ interpretations of ASPECTS scores on non-contrast CT scans … ,” noted Michalis Papadakis, CEO and co-founder of Brainomix. “Our technology supports these physicians who are making time-sensitive, critical decisions around transfer and treatment, strengthening networks and facilitating an improved stroke service.”
(Editor’s note: For related content, see “Portable MRI System Gets FDA Nod for AI-Powered Brain Imaging Software” and “TeraRecon Launches AI-Driven Neuroimaging Platform.”)
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
